Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2004.05.166 on May 10 2004

Journal of Clinical Oncology, Vol 22, No 12 (June 15), 2004: pp. 2284-2293
© 2004 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ayers, M.
Right arrow Articles by Pusztai, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ayers, M.
Right arrow Articles by Pusztai, L.
Related Articles
Right arrowRelated Editorial

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

M. Ayers, W.F. Symmans, J. Stec, A.I. Damokosh, E. Clark, K. Hess, M. Lecocke, J. Metivier, D. Booser, N. Ibrahim, V. Valero, M. Royce, B. Arun, G. Whitman, J. Ross, N. Sneige, G.N. Hortobagyi, L. Pusztai

From Millennium Pharmaceuticals Inc, Cambridge, MA; and the Departments of Pathology, Biostatistics, Breast Medical Oncology, and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Lajos Pusztai, MD, Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 424, 1515 Holcombe Blvd, Houston, TX 77030-4009; e-mail: lpusztai{at}mdanderson.org or Andrew.Damokosh{at}mpi.com

PURPOSE: The goal of this study was to examine the feasibility of developing a multigene predictor of pathologic complete response (pCR) to sequential weekly paclitaxel and fluorouracil + doxorubicin + cyclophosphamide (T/FAC) neoadjuvant chemotherapy regimen for breast cancer.

PATIENTS AND METHODS: All patients underwent one-time pretreatment fine-needle aspiration to obtain RNA from the cancer for transcriptional profiling using cDNA arrays containing 30,721 human sequence clones. Analysis was performed after profiling, and 42 patients' clinical results were available, 24 of which were used for predictive marker discovery; 18 patients' results were used as an independent validation set.

RESULTS: Thirty-one percent of patients had pCR (six discovery and seven validation), defined as disappearance of all invasive cancer in the breast after completion of chemotherapy. We could identify no single marker that was sufficiently associated with pCR to be used as an individual predictor. A multigene model with 74 markers (P ≤ .09) was built using data from the discovery samples and tested on the validation samples. Overall, a 78% (14 of 18) predictive accuracy was observed, with a 100% (three of three) positive predictive value for pCR, a 73% (11 of 15) negative predictive value, a sensitivity of 43% (three of seven), and a specificity of 100% (11 of 11). The expected response rate to T/FAC neoadjuvant therapy in unselected patients is 28%.

CONCLUSION: Our results suggest that transcriptional profiling has the potential to identify a gene expression pattern in breast cancer that may lead to clinically useful predictors of pCR to T/FAC neoadjuvant therapy.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Related Editorial

  • Trawling for Genes That Predict Response to Breast Cancer Adjuvant Therapy
    Matthew Ellis and Karla Ballman
    JCO 2004 22: 2267-2269 [Full Text]


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. Sauer, N. Schneiderhan-Marra, C. Kazmaier, K. Hutzel, K. Koretz, R. Muche, R. Kreienberg, T. Joos, and H. Deissler
Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion
Clin. Cancer Res., June 1, 2008; 14(11): 3345 - 3353.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Oncologist, May 1, 2008; 13(5): 477 - 493.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C.-C. Huang and M. Bredel
Use of Gene Signatures to Improve Risk Estimation in Cancer
JAMA, April 2, 2008; 299(13): 1605 - 1606.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Chanrion, V. Negre, H. Fontaine, N. Salvetat, F. Bibeau, G. M. Grogan, L. Mauriac, D. Katsaros, F. Molina, C. Theillet, et al.
A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer
Clin. Cancer Res., March 15, 2008; 14(6): 1744 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear
Measuring Circulating Tumor Cells As a Surrogate End Point for Adjuvant Therapy of Breast Cancer: What Do They Mean and What Should We Do About Them?
J. Clin. Oncol., March 10, 2008; 26(8): 1195 - 1197.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
Ann. Onc., February 1, 2008; 19(2): 223 - 232.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Bonadonna, P. Valagussa, and U. Veronesi
Lessons From the Initial Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Studies in Operable Breast Cancer
J. Clin. Oncol., January 20, 2008; 26(3): 342 - 344.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Wong, D. S.A. Nuyten, A. Regev, M. Lin, A. S. Adler, E. Segal, M. J. van de Vijver, and H. Y. Chang
Revealing Targeted Therapy for Human Cancer by Gene Module Maps
Cancer Res., January 15, 2008; 68(2): 369 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. K.T. Tan, L. K. Tan, K. Yu, P. H. Tan, M. Lee, L. H. Sii, C. Y. Wong, G. H. Ho, A. W.Y. Yeo, P. K.H. Chow, et al.
Clinical Validation of a Customized Multiple Signature Microarray for Breast Cancer
Clin. Cancer Res., January 15, 2008; 14(2): 461 - 469.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
Ann. Onc., December 1, 2007; 18(12): 1927 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Lusa, L. M. McShane, J. F. Reid, L. De Cecco, F. Ambrogi, E. Biganzoli, M. Gariboldi, and M. A. Pierotti
Challenges in Projecting Clustering Results Across Gene Expression Profiling Datasets
J Natl Cancer Inst, November 21, 2007; 99(22): 1715 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Pusztai, K. Anderson, and K. R. Hess
Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer
Clin. Cancer Res., October 15, 2007; 13(20): 6080 - 6086.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Minna, L. Girard, and Y. Xie
Tumor mRNA Expression Profiles Predict Responses to Chemotherapy
J. Clin. Oncol., October 1, 2007; 25(28): 4329 - 4336.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug
Breast cancer prognostication and prediction in the postgenomic era
Ann. Onc., August 1, 2007; 18(8): 1293 - 1306.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Mazouni, F. Peintinger, S. Wan-Kau, F. Andre, A. M. Gonzalez-Angulo, W. F. Symmans, F. Meric-Bernstam, V. Valero, G. N. Hortobagyi, and L. Pusztai
Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
J. Clin. Oncol., July 1, 2007; 25(19): 2650 - 2655.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. N. Harris, F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B.-A. Lesnikoski, et al.
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara
Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer
Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Chang
HER2 Inhibition: From Discovery to Clinical Practice
Clin. Cancer Res., January 1, 2007; 13(1): 1 - 3.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. K Gruvberger-Saal, H. E Cunliffe, K. M Carr, and I. A Hedenfalk
Microarrays in breast cancer research and clinical practice - the future lies ahead
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1017 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Sorlie, C. M. Perou, C. Fan, S. Geisler, T. Aas, A. Nobel, G. Anker, L. A. Akslen, D. Botstein, A.-L. Borresen-Dale, et al.
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.
Mol. Cancer Ther., November 1, 2006; 5(11): 2914 - 2918.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
F. Bertucci, D. Birnbaum, and A. Goncalves
Proteomics of Breast Cancer: Principles and Potential Clinical Applications
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. W. Watters and C. J. Roberts
Developing gene expression signatures of pathway deregulation in tumors.
Mol. Cancer Ther., October 1, 2006; 5(10): 2444 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Kreike, H. Halfwerk, P. Kristel, A. Glas, H. Peterse, H. Bartelink, and M. J. van de Vijver
Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.
Clin. Cancer Res., October 1, 2006; 12(19): 5705 - 5712.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. R. Hess, K. Anderson, W. F. Symmans, V. Valero, N. Ibrahim, J. A. Mejia, D. Booser, R. L. Theriault, A. U. Buzdar, P. J. Dempsey, et al.
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
J. Clin. Oncol., September 10, 2006; 24(26): 4236 - 4244.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Pusztai, C. Mazouni, K. Anderson, Y. Wu, and W. F. Symmans
Molecular Classification of Breast Cancer: Limitations and Potential
Oncologist, September 1, 2006; 11(8): 868 - 877.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Paik, G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F. L. Baehner, D. Watson, J. Bryant, et al.
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer
J. Clin. Oncol., August 10, 2006; 24(23): 3726 - 3734.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
W. S. Dalton and S. H. Friend
Cancer biomarkers--an invitation to the table.
Science, May 26, 2006; 312(5777): 1165 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al.
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Thuerigen, A. Schneeweiss, G. Toedt, P. Warnat, M. Hahn, H. Kramer, B. Brors, C. Rudlowski, A. Benner, F. Schuetz, et al.
Gene Expression Signature Predicting Pathologic Complete Response With Gemcitabine, Epirubicin, and Docetaxel in Primary Breast Cancer
J. Clin. Oncol., April 20, 2006; 24(12): 1839 - 1845.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kaufmann, G. N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J.-U. Blohmer, W. Eiermann, R. Jackesz, W. Jonat, et al.
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
J. Clin. Oncol., April 20, 2006; 24(12): 1940 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Anderson, K. R. Hess, M. Kapoor, S. Tirrell, J. Courtemanche, B. Wang, Y. Wu, Y. Gong, G. N. Hortobagyi, W. F. Symmans, et al.
Reproducibility of Gene Expression Signature-Based Predictions in Replicate Experiments
Clin. Cancer Res., March 15, 2006; 12(6): 1721 - 1727.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. H. Roukos, E. Paraskevaidis, and A. M. Kappas
Surgery in the Era of Gene Expression Profiling-Based Prediction and Individualized, Neoadjuvant Breast Cancer Therapy: The Beginning of the End?
Ann. Surg. Oncol., March 1, 2006; 13(3): 433 - 435.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J S Reis-Filho, C Westbury, and J-Y Pierga
The impact of expression profiling on prognostic and predictive testing in breast cancer.
J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
V. Nygaard and E. Hovig
Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling
Nucleic Acids Res., February 9, 2006; 34(3): 996 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. K. Dressman, C. Hans, A. Bild, J. A. Olson, E. Rosen, P. K. Marcom, V. B. Liotcheva, E. L. Jones, Z. Vujaskovic, J. Marks, et al.
Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy
Clin. Cancer Res., February 1, 2006; 12(3): 819 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. L. Gomez, S. L. Santillana, C. S. Vallejos, R. Velarde, J. Sanchez, X. Wang, N. L. Bauer, R. D. Hockett, V. J. Chen, C. Niyikiza, et al.
A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression
Clin. Cancer Res., February 1, 2006; 12(3): 832 - 838.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. B. Travis, C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, C. B. Begg, N. Caporaso, S. Chanock, A. DeMichele, et al.
Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
J Natl Cancer Inst, January 4, 2006; 98(1): 15 - 25.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. T. Hennessy, G. N. Hortobagyi, R. Rouzier, H. Kuerer, N. Sneige, A. U. Buzdar, S. W. Kau, B. Fornage, A. Sahin, K. Broglio, et al.
Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy
J. Clin. Oncol., December 20, 2005; 23(36): 9304 - 9311.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
F. A. Holmes and J. D. Liticker
Pharmacogenomics of Tamoxifen in a Nutshell--And Who Broke the Nutcracker?
J. Oncol. Pract, November 1, 2005; 1(4): 155 - 159.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. A. Koike Folgueira, D. M. Carraro, H. Brentani, D. F. da Costa Patrao, E. M. Barbosa, M. M. Netto, J. R. F. Caldeira, M. L. H. Katayama, F. A. Soares, C. T. Oliveira, et al.
Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer
Clin. Cancer Res., October 15, 2005; 11(20): 7434 - 7443.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, J. Wu, G. Mariani, J. Rodriguez, M. Carcangiu, D. Watson, et al.
Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
J. Clin. Oncol., October 10, 2005; 23(29): 7265 - 7277.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Brenton, L. A. Carey, A. A. Ahmed, and C. Caldas
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
J. Clin. Oncol., October 10, 2005; 23(29): 7350 - 7360.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Espinosa, J.A. F. Vara, A. Redondo, J.J. Sanchez, D. Hardisson, P. Zamora, F. G. Pastrana, P. Cejas, B. Martinez, A. Suarez, et al.
Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study
J. Clin. Oncol., October 10, 2005; 23(29): 7278 - 7285.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Gonzalez-Angulo, S. E. McGuire, T. A. Buchholz, S. L. Tucker, H. M. Kuerer, R. Rouzier, S.-W. Kau, E. H. Huang, P. Morandi, A. Ocana, et al.
Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy
J. Clin. Oncol., October 1, 2005; 23(28): 7098 - 7104.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. van de Vijver
Gene-Expression Profiling and the Future of Adjuvant Therapy
Oncologist, October 1, 2005; 10(suppl_2): 30 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rouzier, C. M. Perou, W. F. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. R. Hess, J. Stec, M. Ayers, P. Wagner, et al.
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Clin. Cancer Res., August 15, 2005; 11(16): 5678 - 5685.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
J. Stec, J. Wang, K. Coombes, M. Ayers, S. Hoersch, D. L. Gold, J. S Ross, K. R. Hess, S. Tirrell, G. Linette, et al.
Comparison of the Predictive Accuracy of DNA Array-Based Multigene Classifiers across cDNA Arrays and Affymetrix GeneChips
J. Mol. Diagn., August 1, 2005; 7(3): 357 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S R D Johnston
Clinical trials of intracellular signal transductions inhibitors for breast cancer -- a strategy to overcome endocrine resistance
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S145 - S157.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. F. Reid, L. Lusa, L. De Cecco, D. Coradini, S. Veneroni, M. G. Daidone, M. Gariboldi, and M. A. Pierotti
Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome
J Natl Cancer Inst, June 15, 2005; 97(12): 927 - 930.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Hannemann, H. M. Oosterkamp, C. A.J. Bosch, A. Velds, L. F.A. Wessels, C. Loo, E. J. Rutgers, S. Rodenhuis, and M. J. van de Vijver
Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer
J. Clin. Oncol., May 20, 2005; 23(15): 3331 - 3342.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. C. Hartmann, K. H. Lu, G. P. Linette, W. A. Cliby, K. R. Kalli, D. Gershenson, R. C. Bast, J. Stec, N. Iartchouk, D. I. Smith, et al.
Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy
Clin. Cancer Res., March 15, 2005; 11(6): 2149 - 2155.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. J. van't Veer, S. Paik, and D. F. Hayes
Gene Expression Profiling of Breast Cancer: A New Tumor Marker
J. Clin. Oncol., March 10, 2005; 23(8): 1631 - 1635.
[Full Text] [PDF]

Home page
 JCOHome page
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. J. Duffy
Predictive Markers in Breast and Other Cancers: A Review
Clin. Chem., March 1, 2005; 51(3): 494 - 503.
[Abstract] [Full Text] [PDF] <